PET/CT radiomics in breast cancer : Mind the step
Copyright © 2020 Elsevier Inc. All rights reserved..
The aim of the present review was to assess the current status of positron emission tomography/computed tomography (PET/CT) radiomics research in breast cancer, and in particular to analyze the strengths and weaknesses of the published papers in order to identify challenges and suggest possible solutions and future research directions. Various combinations of the terms "breast", "radiomic", "PET", "radiomics", "texture", and "textural" were used for the literature search, extended until 8 July 2019, within the PubMed/MEDLINE database. Twenty-six articles fulfilling the inclusion/exclusion criteria were retrieved in full text and analyzed. The studies had technical and clinical objectives, including diagnosis, biological characterization (correlation with histology, molecular subtypes and IHC marker expression), prediction of response to neoadjuvant chemotherapy, staging, and outcome prediction. We reviewed and discussed the selected investigations following the radiomics workflow steps related to the clinical, technical, analysis, and reporting issues. Most of the current evidence on the clinical role of PET/CT radiomics in breast cancer is at the feasibility level. Harmonized methods in image acquisition, post-processing and features calculation, predictive models and classifiers trained and validated on sufficiently representative datasets, adherence to consensus guidelines, and transparent reporting will give validity and generalizability to the results.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:188 |
---|---|
Enthalten in: |
Methods (San Diego, Calif.) - 188(2021) vom: 01. Apr., Seite 122-132 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Sollini, Martina [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 01.11.2021 Date Revised 01.11.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.ymeth.2020.01.007 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM305752367 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM305752367 | ||
003 | DE-627 | ||
005 | 20231225121850.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.ymeth.2020.01.007 |2 doi | |
028 | 5 | 2 | |a pubmed24n1019.xml |
035 | |a (DE-627)NLM305752367 | ||
035 | |a (NLM)31978538 | ||
035 | |a (PII)S1046-2023(19)30263-4 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Sollini, Martina |e verfasserin |4 aut | |
245 | 1 | 0 | |a PET/CT radiomics in breast cancer |b Mind the step |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 01.11.2021 | ||
500 | |a Date Revised 01.11.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2020 Elsevier Inc. All rights reserved. | ||
520 | |a The aim of the present review was to assess the current status of positron emission tomography/computed tomography (PET/CT) radiomics research in breast cancer, and in particular to analyze the strengths and weaknesses of the published papers in order to identify challenges and suggest possible solutions and future research directions. Various combinations of the terms "breast", "radiomic", "PET", "radiomics", "texture", and "textural" were used for the literature search, extended until 8 July 2019, within the PubMed/MEDLINE database. Twenty-six articles fulfilling the inclusion/exclusion criteria were retrieved in full text and analyzed. The studies had technical and clinical objectives, including diagnosis, biological characterization (correlation with histology, molecular subtypes and IHC marker expression), prediction of response to neoadjuvant chemotherapy, staging, and outcome prediction. We reviewed and discussed the selected investigations following the radiomics workflow steps related to the clinical, technical, analysis, and reporting issues. Most of the current evidence on the clinical role of PET/CT radiomics in breast cancer is at the feasibility level. Harmonized methods in image acquisition, post-processing and features calculation, predictive models and classifiers trained and validated on sufficiently representative datasets, adherence to consensus guidelines, and transparent reporting will give validity and generalizability to the results | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Review | |
650 | 4 | |a Breast cancer | |
650 | 4 | |a Image mining steps | |
650 | 4 | |a Positron emission tomography/computed tomography | |
650 | 4 | |a Radiomics workflow | |
650 | 4 | |a Texture analysis | |
650 | 7 | |a Radiopharmaceuticals |2 NLM | |
650 | 7 | |a Fluorodeoxyglucose F18 |2 NLM | |
650 | 7 | |a 0Z5B2CJX4D |2 NLM | |
700 | 1 | |a Cozzi, Luca |e verfasserin |4 aut | |
700 | 1 | |a Ninatti, Gaia |e verfasserin |4 aut | |
700 | 1 | |a Antunovic, Lidija |e verfasserin |4 aut | |
700 | 1 | |a Cavinato, Lara |e verfasserin |4 aut | |
700 | 1 | |a Chiti, Arturo |e verfasserin |4 aut | |
700 | 1 | |a Kirienko, Margarita |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Methods (San Diego, Calif.) |d 1990 |g 188(2021) vom: 01. Apr., Seite 122-132 |w (DE-627)NLM087818051 |x 1095-9130 |7 nnns |
773 | 1 | 8 | |g volume:188 |g year:2021 |g day:01 |g month:04 |g pages:122-132 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ymeth.2020.01.007 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 188 |j 2021 |b 01 |c 04 |h 122-132 |